Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comparing BRAF mutation status in matched primary and metastatic cutaneous melanomas: implications on optimized targeted therapy.

Experimental and molecular pathology - 1 Dec 2014

Saroufim Maya, Habib Robert H, Gerges Rita, Saab Jad, Loya Asif, Amr Samir S, Sheikh Salwa, Satti Mohammad, Oberkanins Christian, Khalifeh Ibrahim

Abstract excerpt

BACKGROUND: Selective BRAF inhibitors have shown dramatic results with regard to improving outcome in patients with melanoma. Testing the BRAF status in matched primary and metastatic melanomas to optimize individual targeted therapy is not well investigated. METHODS: Extended BRAF testing using PCR for 9 mutations and VE1 immunohistochemistry for BRAF V600E detection on 95 lesions including 40 primary melanomas...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Mutational Analysis
Share to Immunohistochemistry

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Melanoma

Share to Molecular Targeted Therapy

Share to Neoplasm Metastasis

Share to Proto-Oncogene Proteins B-raf

Share to Reverse Transcriptase Polymerase Chain Reaction

Share to Skin Neoplasms

Source

Identifiers

PMID: 25236573
DOI: 10.1016/j.yexmp.2014.09.008

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comparing BRAF mutation status in matched primary and metastatic cutaneous melanomas: implications on optimized targeted therapy.PMID 25236573Read ↗

Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma.Semantic proximity Read ↗

Discordancy in BRAF mutations among primary and metastatic melanoma lesions: clinical implications for targeted therapy.Semantic proximity Read ↗

The significance of BRAF V600E mutation status discordance between primary cutaneous melanoma and brain metastases: The implications for BRAF inhibitor therapy.Semantic proximity Read ↗

Discrepancy in BRAF status among patients with metastatic malignant melanoma: A meta-analysis.Semantic proximity Read ↗

BRAFV600E protein expression in primary cutaneous malignant melanomas and paired metastases.Semantic proximity Read ↗

BRAF Mutation Status Concordance Between Primary Cutaneous Melanomas and Corresponding Metastases: A Review of the Latest Evidence.Semantic proximity Read ↗

Non-V600E/K BRAF Mutations in Metastatic Melanoma: Molecular Description, Frequency, and Effectiveness of Targeted Therapy in a Large National Cohort.Semantic proximity Read ↗

Concordant BRAFV600E mutation status in primary melanomas and associated naevi: implications for mutation testing of primary melanomas.Semantic proximity Read ↗

Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma.Semantic proximity Read ↗

Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicineSemantic proximity Read ↗

Tumor homogeneity between primary and metastatic sites for BRAF status in metastatic melanoma determined by immunohistochemical and molecular testing.Semantic proximity Read ↗

The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.